Immunogenicity and safety of 1-dose versus 2-dose quadrivalent influenza split vaccine in children aged 3 to 8 years

Phase 4, open-label trial of influenza virus vaccine, quadrivalent, split virion in seasonal influenza (3 arms), sponsored by Wuhan Institute of Biological Products. Primary endpoints: Antibody seroconversion rate of HI antibodies against four influenza virus types, Geometric mean titers of HI antibodies against four influenza virus types and 2 more. Started Mar 2022; status: recruiting.